New diabetes clinical trial: Phase I Study of BM2216 ER Vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults

Published on: February 25, 2025 at 11:00PM
Conditions: Diabetic Neuropathies; Diabetes Mellitus
Interventions: Drug: BM2216 Extended-Release tablets（5.5mg）; Drug: Mirogabalin Besilate Tablets; Drug: BM2216 Extended-Release Tablets(11mg); Drug: BM2216 Extended-Release Tablets(16.5mg)
Sponsors: Zhejiang Anglikang Pharmaceutical Co., Ltd.
Completed
https://ift.tt/uwapE18